Cargando…

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

SIMPLE SUMMARY: In randomized trials, both chemotherapy and androgen-receptor signaling inhibitors provided significant survival benefits in patients with metastatic prostate cancer (mPCa). However, it is largely unknown to what extent these therapeutic advances have impacted the general, real-world...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cattrini, Carlo, Soldato, Davide, Rubagotti, Alessandra, Zinoli, Linda, Zanardi, Elisa, Barboro, Paola, Messina, Carlo, Castro, Elena, Olmos, David, Boccardo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650780/ https://www.ncbi.nlm.nih.gov/pubmed/33022939 http://dx.doi.org/10.3390/cancers12102855

Ejemplares similares

Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes
por: Cavo, Alessia, et al.
Publicado: (2018)

To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone
por: Zanardi, Elisa, et al.
Publicado: (2019)

Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients
por: Cattrini, Carlo, et al.
Publicado: (2023)

Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa)
por: Nuzzo, Pier Vitale, et al.
Publicado: (2015)

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death
por: Nuzzo, Pier Vitale, et al.
Publicado: (2012)

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
por: Capaia, Matteo, et al.
Publicado: (2018)

The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome
por: Nuzzo, P. V., et al.
Publicado: (2016)

Differential Proteomic Analysis of Nuclear Matrix in Muscle-Invasive Bladder Cancer: Potential to Improve Diagnosis and Prognosis
por: Barboro, Paola, et al.
Publicado: (2008)

Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer
por: Barboro, P, et al.
Publicado: (2009)

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
por: Lozano, Rebeca, et al.
Publicado: (2020)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?
por: Barranco, Rosario, et al.
Publicado: (2020)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
por: Ferrari, Nicoletta, et al.
Publicado: (2017)

The Role of Nuclear Matrix Proteins Binding to Matrix Attachment Regions (MARs) in Prostate Cancer Cell Differentiation
por: Barboro, Paola, et al.
Publicado: (2012)

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
por: Corsini, Christian, et al.
Publicado: (2023)

Prognostic value of PTEN in de novo diagnosed metastatic prostate cancer
por: Zhang, Jun-Yu, et al.
Publicado: (2021)

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2019)

Regional location of lymph node metastases predicts survival in patients with de novo metastatic prostate cancer
por: Wang, Zhi-Peng, et al.
Publicado: (2022)

Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial
por: Filaci, Gilberto, et al.
Publicado: (2021)

Novel metastatic burden‐stratified risk model in de novo metastatic hormone‐sensitive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer
por: Reverberi, C., et al.
Publicado: (2020)

Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges
por: Sorrentino, Carlo, et al.
Publicado: (2023)

Conditional Survival in de novo Metastatic Urothelial Carcinoma
por: Pal, Sumanta Kumar, et al.
Publicado: (2015)

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
por: Piombino, Claudia, et al.
Publicado: (2023)

Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer
por: Benelli, Roberto, et al.
Publicado: (2019)

HLA Class I Allele Expression and Clinical Outcome in De Novo Metastatic Prostate Cancer
por: Stokidis, Savvas, et al.
Publicado: (2020)

Clinical and oncologic findings of extraprostatic extension on needle biopsy in de novo metastatic prostate cancer
por: Chen, Jun-Ru, et al.
Publicado: (2019)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Impact of Cerebrovascular Disease on Survival Benefits from Local Treatment in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
por: Kim, Tae Jin, et al.
Publicado: (2019)

Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer
por: Terada, Naoki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_139jrqah525rvdmn12nbpnekih